Cost Effectiveness Of Linezolid In Central America

NCT01040585 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2012-03-02

No results posted yet for this study

Summary

The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).

Conditions

  • Ventilator Acquired Pneumonia

Interventions

DRUG

Linezolid

Treatment for VAP as indication approved and as physician criterium.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-03-31
Completion
2011-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01040585 on ClinicalTrials.gov